申请人:Essentialis, Inc.
公开号:EP3545958A1
公开(公告)日:2019-10-02
Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
本发明提供了对受试者立即或长期施用 KATP 通道开放剂(如二氮氧)的某些盐类,以在治疗涉及 KATP 通道的疾病或病症时实现新的药效学、药代动力学、治疗学、生理学、新陈代谢和成分结果。此外,还提供了盐类的药物制剂、给药方法和剂量,这些制剂、给药方法和剂量可实现这些结果,并降低受治疗者不良反应的发生率。此外,还提供了将盐类与其他药物联合给药以治疗人类和动物疾病的方法。